EPP sales (1 and only specific approval for scenesse -no off label option available -and locked down to costly special centres) have plateaued, even though <10% of sufferers have gained access (over 5-10 years) to the ONLY drug that works for their debilitating disease -so effective it’s literally life changing!it is certainly hard to understand how the EPP rollout could be so poorly managed. 95% long term adherence, no significant side effects but less than 10 % market penetration. Wolgen and hay tell us this is better than they expected. An embarrassing disgrace.
EPP sales (1 and only specific approval for scenesse -no off...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.57 |
Change
0.170(1.10%) |
Mkt cap ! $780.1M | |||
| Open | High | Low | Value | Volume |
| $15.38 | $15.63 | $15.25 | $751.5K | 48.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 165 | $15.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.59 | 106 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$15.57 |
Change
0.170 ( 0.95 %) |
||||
| Open | High | Low | Volume | ||
| $15.39 | $15.63 | $15.33 | 8111 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| CUV (ASX) Chart |